Adolor Corp., of Exton, Pa., appointed Melinda Rudolph corporate counsel.

Alnylam Pharmaceuticals Inc., of Cambridge, Mass., appointed Thomas Ulich senior vice president of research and development.

AVI BioPharma Inc., of Portland, Ore., added Gerald Zon to its scientific advisory board.

Axaron Bioscience AG, of Heidelberg, Germany, added Werner Hacke to its clinical advisory board.

Bio-Technology General Corp., of East Brunswick, N.J., elected Jeremy Hayward-Surry and Stephen Jaeger to its board.

Chiron Corp., of Emeryville, Calif., appointed Kenneth Bair senior vice president, head of biopharma research, Chiron BioPharmaceuticals, and Carl Pelzel senior vice president, biopharma commercial operations, Chiron BioPharmaceuticals.

EntreMed Inc., of Rockville, Md., elected Michael Tarnow and Ronald Cape to its board.

Genencor International Inc., of Palo Alto, Calif., promoted Mark Goldsmith to senior vice president, health care and hired John Fiddes as vice president research, health care.

Greenberg Traurig LLP, of Los Angeles, added Mark Krietzman to its intellectual property practice.

Immune Network Ltd., of Vancouver, British Columbia, appointed Peter Boonen to its board.

Insmed Inc., of Richmond, Va., promoted Ronald Gunn to executive vice president.

LION bioscience AG, of Heidelberg, Germany, is adding Klaus Pohle to its supervisory board.

Micrologix Biotech Inc., of Vancouver, British Columbia, established a scientific advisory board, consisting of Lorne Tyrrell, Andre Charette, William Craig and Ving Lee.

Morphotek Inc., of Exton, Pa., appointed Matthias Wabl and Wafik El-Deiry to its scientific advisory board.

OxiGene Inc., of Watertown, Mass., appointed Sten Lindahl to its board.

Panacea Pharmaceuticals Inc., of Gaithersburg, Md., appointed Bijan Almassian chief operating officer.

Protedyne Corp., of Windsor, Conn., appointed Todd Edwards to its scientific/technical staff.

Protein Design Labs Inc., of Fremont, Calif., elected Karen Dawes to its board.

Quorex Pharmaceuticals Inc., of San Diego, appointed Alan Lewis to its board.

Saegis Pharmaceuticals Inc., of Half Moon Bay, Calif., added Thorsten Melcher as vice president, discovery.

Savient Pharmaceuticals Inc., of East Brunswick, N.J., promoted Dov Kanner to executive vice president, chief technical officer.

Serologicals Corp., of Atlanta, added Debbie Radford as director, global customer service; John Spead as director, global environment, health and safety; and Tom McCall as director, engineering and manufacturing technology.

Southern Research Institute, of Birmingham, Ala., named Gregory Gorman director of the new bioanalytical sciences department in the drug development division.

Synta Pharmaceuticals Corp., of Lexington, Mass., appointed Robert Wilson to its board; James Barsoum vice president, biology; Wendy Rieder vice president, intellectual property and legal affairs; and Michael Rivard vice president, business development.

The Immune Response Corp., of Carlsbad, Calif., added Martyn Greenacre to its board.

The Medicines Co., of Parsippany, N.J., said Gary Roubin will work with the company for one year on the Angiomax program.

Viragen Inc., of Plantation, Fla., appointed Richard Stafford to its board.

Zyomyx Inc., of Hayward, Calif., added Thomas McNaughton as vice president, intellectual property and John Lewis as vice president, sales and marketing.